承葛生物完成新一轮超亿元融资，引领精准微生态医疗新范式！

Group 1: Investment and Market Potential - The leading company in the precision microbiota transplantation field, Chengge Biotechnology, has completed a new round of financing exceeding 100 million yuan, led by Yuanwing Investment, marking its second significant capital injection within six months [1] - The global microbiome drug market is projected to exceed 100 billion yuan by 2028, with China expected to grow at three times the global average rate [2] - The recent financing reflects a strong signal that the commercialization of the human microbiome is on the verge of explosive growth [1][2] Group 2: Policy and Regulatory Environment - The National Health Commission of China has included intestinal microbiota transplantation in the medical service project category, with pilot insurance payment programs already underway in regions like Zhejiang and Guangdong [4] - Chengge Biotechnology has been instrumental in establishing five industry standards that are now being implemented, indicating that policy benefits are about to be fully realized [4] Group 3: Technological Advancements and Innovations - Chengge Biotechnology has developed the world's first Precision Microbiota Transplantation Therapy (PMTT) platform, which integrates deep microbiota analysis, precise matching, standardized preparation, and targeted transplantation [9] - The company has established a national microbiota resource platform, recognized by CNAS, to support clinical applications and research in precision microbiota transplantation [11] - Chengge Biotechnology has created six core technology platforms that comprehensively manage the quality of microbiota extraction and transplantation efficacy, serving tens of thousands of patients across over 30 disease types [11] Group 4: Future Outlook and Industry Position - The shift towards microbiome medicine represents a paradigm revolution in healthcare, with Chengge Biotechnology aiming to create a complete closed-loop system from diagnosis to treatment and prevention [15] - The company has positioned itself as a leader in the microbiota transplantation sector, having received the only approval from the Ministry of Science and Technology for human genetic resources and holding full CNAS accreditation [18] - Chengge Biotechnology has provided professional services to over 300 medical institutions, with more than 300,000 instances of microbiota transplantation and testing conducted [18]